Trial reportVaccine2010
Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambaréné, Gabon.
Trial report in Vaccine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review on malaria and dengue vaccines for the effective management of these mosquito borne diseases: Improving public health.Human vaccines & immunotherapeutics · 2024Pooled it
- Exploratory analysis of the effect of helminth infection on the immunogenicity and efficacy of the asexual blood-stage malaria vaccine candidate GMZ2.PLoS neglected tropical diseases · 2021Trial
- Controlled Human Malaria Infection of Healthy Adults With Lifelong Malaria Exposure to Assess Safety, Immunogenicity, and Efficacy of the Asexual Blood Stage Malaria Vaccine Candidate GMZ2.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Trial
- Malaria incidence in children in South-West Burkina Faso: comparison of active and passive case detection methods.PloS one · 2014Trial
- A flow cytometry-based workflow for detection and quantification of anti-plasmodial antibodies in vaccinated and naturally exposed individuals.Malaria journal · 2012Trial
- A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children.PloS one · 2011Trial
- Cellular Immune Response and T Cell Epitope Mapping ofVaccines · 2026Article
- Article
- The Need for Novel Asexual Blood-Stage Malaria Vaccine Candidates forBiomolecules · 2024Review
- Cloning and Recombinant Protein Expression in Lactococcus lactis.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Cellular and antibody response in GMZ2-vaccinated Gabonese volunteers in a controlled human malaria infection trial.Malaria journal · 2022Article
- Article
- GMZ2 Vaccine-Induced Antibody Responses, Naturally Acquired Immunity and the Incidence of Malaria in Burkinabe Children.Frontiers in immunology · 2022Article
- Plasmodium falciparum merozoite surface protein 3 as a vaccine candidate: a brief review.Revista do Instituto de Medicina Tropical de Sao Paulo · 2022Review
- Preclinical development of a Pfs230-Pfs48/45 chimeric malaria transmission-blocking vaccine.NPJ vaccines · 2021Article
- Development of sustainable research excellence with a global perspective on infectious diseases: Centre de Recherches Médicales de Lambaréné (CERMEL), Gabon.Wiener klinische Wochenschrift · 2021Review
- Effect of hookworm infection and anthelmintic treatment on naturally acquired antibody responses against the GMZ2 malaria vaccine candidate and constituent antigens.BMC infectious diseases · 2021Article
- Non-Invasive Antibody Assessment in Saliva to Determine SARS-CoV-2 Exposure in Young Children.Frontiers in immunology · 2021Observational
- Antibody Correlates of Protection from ClinicalThe American journal of tropical medicine and hygiene · 2020Review
- Genetic polymorphism of merozoite surface protein-3 in Myanmar Plasmodium falciparum field isolates.Malaria journal · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Malaria is still one of the major public health threats in sub-Saharan Africa. An effective vaccine could be a sustainable control measure that can be integrated into existing health infrastructures. The malaria vaccine candidate GMZ2 is a recombinant fusion protein of conserved parts of Plasmodium falciparum Glutamate Rich Protein and Merozoite Surface Protein 3 adjuvanted with aluminium hydroxide. GMZ2 is immunogenic and well tolerated in malaria-naive adults from Germany. To assess safety and immunogenicity in malaria-exposed individuals, 40 adults from Lambaréné, Gabon were randomly assigned to receive either 100 μg GMZ2 or a rabies control vaccine three times in monthly intervals. Both vaccines were well tolerated. One month after a full course of vaccination, GMZ2-vaccinated individuals had 1.4-fold (95% confidence interval: [1.1, 1.7]) higher baseline-corrected anti-GMZ2 antibody levels and more GMZ2-specific memory B-cells compared to the rabies group (p=0.039), despite a high prevalence of GMZ2-specific immune reactivity due to previous intense exposure to P. falciparum.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.